1795 PREDICTIVE VALUE OF KIT EXPRESSION IN THE EFFECACY OF SORAFENIB IN TREATING METASTATIC RENAL CELL CARCINOMA WITH SARCOMATOID FEATURE

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced II1 Apr 20101795 PREDICTIVE VALUE OF KIT EXPRESSION IN THE EFFECACY OF SORAFENIB IN TREATING METASTATIC RENAL CELL CARCINOMA WITH SARCOMATOID FEATURE Hai Liang Zhang, Ding Wei Ye, Li Feng Yang, Xu Dong Yao, Yao Zhu, Yi Jun Shen, and Yi Ping Zhu Hai Liang ZhangHai Liang Zhang More articles by this author , Ding Wei YeDing Wei Ye More articles by this author , Li Feng YangLi Feng Yang More articles by this author , Xu Dong YaoXu Dong Yao More articles by this author , Yao ZhuYao Zhu More articles by this author , Yi Jun ShenYi Jun Shen More articles by this author , and Yi Ping ZhuYi Ping Zhu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1719AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The prognosis of metastatic renal cell carcinomas with sarcomatoid feature are simply poor, and there are few data about the efficacy of targeted therapies to these malignancies. We planned to detect the expression of KIT (stem cell factor) in metastatic renal cell carcinomas with sarcomatoid feature in the primary tumor, and to reveal its predictive value in the effect of Sorafenib treatment and survival of the patients. METHODS Seventeen patients were pathologically diagnosed as metastatic renal cell carcinoma with sarcomatoid feature or pure sarcomatoid renal cell carcinomas. Sorafenib were given at the dosage of 400mg orally twice daily as a second-line treatment after cytokine therapy. Percentage of sarcomatoid feature in the whole tumor was calculated in every specimen. The expressions of KIT were tested immunohistochemically in the 17 specimens of primary renal tumor. The relationships between KIT status and treatment effect was compared and discussed. Kaplan-Meier method was used to determine the survival between KIT-positive and KIT-negative patients. RESULTS Twelve out of 17 specimens (70.6%) were demonstrated overexpression of KIT. No statistical significance was seen in the correlation between KIT expression and tumor size, pathological subtype, percentage of sarcomatoid feature, and P53 expression. KIT-positive patients had higher disease control rate compared to KIT-negative patients (p=0.036). The estimated median survival time was 92 weeks for KIT-positive patients and 44 weeks for KIT negative patients, p=0.007. CONCLUSIONS Sorafenib is relatively effective to metastatic renal cell carcinomas with sarcomatoid feature as a second-line treatment. The expression of KIT in the primary tumor is an important survival predicting factor when these patients are treated with Sorafenib. Table. Crosstabulation between expression of KIT and effect of treatment Effect Total CR+PR+SD PD KIT Negative 1 4 5 Positive 9 3 12 Total 10 7 17 X2=4.408, p=0.036 Shanghai, People's Republic of China© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e696 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hai Liang Zhang More articles by this author Ding Wei Ye More articles by this author Li Feng Yang More articles by this author Xu Dong Yao More articles by this author Yao Zhu More articles by this author Yi Jun Shen More articles by this author Yi Ping Zhu More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...